Recent corporate updates from Immuneering Corporation highlight strong financial discipline, reporting a robust cash position that provides an operational runway extending into the year 2029. Key clinical milestones include dosing the first patients in its global, randomized pivotal Phase 3 MAPKeeper 301 trial evaluating its lead oncology candidate, atebimetinib, combined with chemotherapy in first-line metastatic pancreatic cancer, building upon favorable survival data presented at major medical congresses.